PNAL

(redirected from Persistently Normal ALT)
AcronymDefinition
PNALPersistently Normal ALT (Alanine Amino Transaminase) Levels
PNALPalmerston North Airport Limited (New Zealand)
References in periodicals archive ?
They suggested that CLD, in most of the cases is asymptomatic until its terminal stages and also significant hepatic necrosis and fibrosis may be present in persistently normal ALT levels in many of the patients of HBV, HCV carriers and in patients with nonalcoholic fatty liver disease.
It is important to underline that some inactive carriers may have HBV DNA levels greater than 2000 IU/ml (usually below 20,000 IU/ml), despite their persistently normal ALT levels (1,6,9) In these carriers the follow-up should be much more condensed, with ALT determinations every 3 months and HBV DNA measurements every 6-12 months for at least 3 years (1).
Although the optimal definition of persistently normal ALT (PNALT) levels has not been established, the fluctuating nature of chronic HBV infection reasonably justifies serial ALT determinations.
4,16,17) In the present study, we aimed to examine the prevalence of HBV genotypes and G1896A mutation and A1762T/G1764A double mutations and their association with status of chronic hepatitis B in HBV-infected patients with persistently normal ALT and low serum HBV-DNA levels in Liaoning, a northeast province of China.
HCV carriers with persistently normal ALT levels : Not too much healthy, not true patients.
The dependence on ALT levels as an indicator of the need for treatment has been called into question because significant fibrosis and inflammation can occur in patients with chronic HBV infection despite persistently normal ALT levels.
and European consensus statements have recommended against treatment in patients with chronic hepatitis C virus (HCV) and persistently normal ALT levels (who account for one third of those with HCV) based on a lack of data and concerns that treatment in this population might cause ALT levels to flare.
and European consensus statements have recommended against treatment in patients with chronic hepatitis C virus (HCV) and persistently normal ALT levels (who account for one-third of those with HCV) based on a lack of data and concerns that treatment in this population might cause ALT levels to flare.
Although the definition of chronic hepatic injury by increased ALT is widely accepted, 15-50% of patients with chronic hepatitis C have persistently normal ALT (51,60-62).
1-4) Thus, at least two different subsets of HCVPNALT carriers exist: patients with temporal ALT fluctuations, that could be within the normal range for several months, and true 'biochemically silent' carriers showing persistently normal ALT values.
2) Therapy is not recommended for patients with persistently normal ALT levels, advanced cirrhosis, current ethanol intake, intravenous drug use, major depression or severe psychiatric disease, renal transplant, untreated thyroid, or autoimmune disorders, or for pregnant or breast feeding women.